This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Alignment Healthcare (ALHC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Alignment Healthcare (ALHC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alignment Healthcare (ALHC) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of +128.57% and +1.30%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
BrightSpring Health Services, Inc. (BTSG) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
BrightSpring Health Services, Inc. (BTSG) delivered earnings and revenue surprises of +11.11% and +5.46%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging CVS Health (CVS) This Year?
by Zacks Equity Research
Here is how CVS Health (CVS) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for October 7th
by Zacks Equity Research
EGAN, STNE and ALHC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 7, 2025.
New Strong Buy Stocks for October 7th
by Zacks Equity Research
ALHC, STNE, EGAN, PAHC and MTG have been added to the Zacks Rank #1 (Strong Buy) List on October 7, 2025.
What Makes Alignment Healthcare (ALHC) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Alignment Healthcare (ALHC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
by Zacks Equity Research
Here is how Akebia Therapeutics (AKBA) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Clover Health Pre-Q2 Earnings Analysis: Buy, Sell or Hold the Stock?
by Indrajit Bandyopadhyay
CLOV's second-quarter results are likely to reflect strong Medicare Advantage membership growth and expansion and deeper integration of Clover Assistant.
Alignment Healthcare (ALHC) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Alignment Healthcare (ALHC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.